Related Experiment Video
Updated: Jan 8, 2026

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic
Anna C Renner1, Robert B Kargbo2
1North Dakota State University, Fargo, North Dakota 58108-6050, United States.
Abstract:
Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT2A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure-activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that align with clinical workflow and improve therapeutic predictability for psychiatric disorders.
Related Concept Videos
CNS Stimulants: Psychedelic Agents
Microorganisms in Medicine and Therapeutics
What is Genetic Engineering?
Drug Discovery: Overview
Drugs Affecting Neurotransmitter Synthesis

